InSphero Significantly Expands Corporate Headquarters to Meet Growth in BioPharmaceutical Research Partnerships
Move optimally positions InSphero to build on its business development, scientific research, and operational teams.
Schlieren, Switzerland – June 18, 2020 InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company will relocate its corporate headquarters and research and bioproduction laboratories to a larger facility in the Bio-Technopark Schlieren-Zürich life sciences building complex, positioned in the heart of the greater Zürich biotechnology hub. The new headquarters will almost double the company’s laboratory space and administrative office space, and optimally positions InSphero to expand as the company prepares for its next phase of growth as a biotechnology company that is transforming complex disease discovery, translational toxicology, and phenotypic preclinical modelling to advance human health.
“This move represents a significant milestone in InSphero’s history and marks the next step in our evolution as an innovative biotech that is redefining traditional drug discovery and safety testing paradigms for the pharmaceutical industry,” says InSphero CEO and co-founder Jan Lichtenberg, PhD. “Our new headquarters will provide an inspiring work environment for our employees, with state-of-the-art laboratories that will enable our scientists to optimize R&D workflows that incorporate our trailblazing technology and better support our growing roster of partnerships with researchers in pharma, biotech, and academia.”
InSphero has signed a long-term lease with Bio-Technopark Schlieren-Zürich, with an option to further expand within the next 3-5 years. The move, which will be completed on July 1, 2020, will not impact laboratory operations or customer service.
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.
Frank Junker, PhD
Chief Business Officer
Phone +41 44 5150490
InSphero’s new corporate headquarters is located at Wagistrasse 27A, Schlieren, Switzerland.